Addex Therapeutics SA, of Geneva, disclosed positive preclinical data for its GABAB receptor-positive allosteric modulator in a rodent model of chronic alcohol dependence. The Addex alcoholism candidate, ADX71441, demonstrated robust and dose-dependent suppression of alcohol intake in animals lasting 24 hours. ADX71441 is an oral small molecule, with potential for once-daily dosing. In other news, Addex said dipraglurant demonstrated dose-dependent mGlu5 receptor occupancy in a nonhuman primate

Quest Diagnostics Inc., of Madison, N.J., appointed Jim Davis senior vice president, diagnostic solutions...Vanda Pharmaceuticals Inc., of Washington, named Paolo Baroldi senior vice president and chief medical officer

Andrei Gudkov, who is chief scientific officer at Cleveland BioLabs as well as senior vice president of basic science at the Roswell Park Cancer Institute and the paper's corresponding author, told BioWorld Today that after the fact, "from an engineering perspective, it makes sense" that TLR5 agonists should work in the liver, though he also cheerfully acknowledged the findings were at first surprising to him and his colleagues

Specific details were not provided, but Craig Audet, senior vice president of operations and head of global regulatory affairs, cited nonclinical issues

In granting the motion, the judge ruled that the plaintiffs failed to offer any reliable evidence that Mr. Cooper's disease was caused by Actos (pioglitazone HC1)," said Kenneth D. Greisman, senior vice president, general counsel, Takeda Pharmaceuticals U.S.A. Inc

His own background includes tenure as a senior vice president at Merck

During a Tuesday session included as part of the orphan disease forum, Rogerio Vivaldi, senior vice president and head of the rare disease unit at Sanofi SA subsidiary Genzyme, recounted the moment 21 years ago when he was working as a physician and was faced with the first Gaucher disease patient he infused with enzyme replacement therapy Cerezyme (imiglucerase alfa

The price points, frankly, at some point are going to be unsustainable," said Sunil Patel, senior vice president and chief business officer of Oncomed Pharmaceuticals Inc

asked George Golumbeski, senior vice president of business development for Celgene Corp

asked George Golumbeski, senior vice president of business development for Celgene Corp

The government has come a long ways since 9/11, but we have a long way to go," Francesca Cook, senior vice president of policy and government affairs at PharmAthene Inc., told BioWorld Insight

Testifying at Thursday's hearing, Christine Simmon, senior vice president for policy and strategic alliances for the Generic Pharmaceutical Association, expressed support for the "building blocks" approach of the House draft

During a Tuesday session included as part of the orphan disease forum, Rogerio Vivaldi, senior vice president and head of the rare disease unit at Sanofi SA subsidiary Genzyme, recounted the moment 21 years ago when he was working as a physician and was faced with the first Gaucher disease patient he infused with enzyme replacement therapy Cerezyme (imiglucerase alfa

Inc., of Whitehouse Station, N.J., and senior vice president of Merck Research Laboratories, said more than half of the 61 deals the company did last year – the most in its history – involved academic partners...Atul Saran, senior vice president of corporate development and ventures at MedImmune, part of London-based AstraZeneca plc, who spoke on a Monday panel on biotech partnering with academia, said the pharma/academia model doesn't threaten the role of biotechs in drug development

Inc., of Whitehouse Station, N.J., and senior vice president of Merck Research Laboratories, said more than half of the 61 deals the company did last year – the most in its history – involved academic partners...Atul Saran, senior vice president of corporate development and ventures at MedImmune, part of London-based AstraZeneca plc, who spoke on a Monday panel on biotech partnering with academia, said the pharma/academia model doesn't threaten the role of biotechs in drug development

The Needham, Mass.-based firm has generated buzz with its lead program, rindopepimut, an immunotherapy targeting epidermal growth factor variant III, in pivotal testing in glioblastoma multiforme, but the company's goal is really to combine several of its internal programs, said Tom Davis, senior vice president and chief medical officer

By the time physicians see patients with a serious or life-threatening infection, they must start treating empirically, said Barry Eisenstein, senior vice president of scientific affairs at Cubist Pharmaceuticals Inc., which is developing a pipeline of anti-infectives

Company principals knew the compound intimately, since two of Armetheon's co-founders – Pascal Druzgala, senior vice president of research and chief scientific officer, and Peter Milner, executive chairman – had formed ARYx in the late 1990s

According to Frank Bennett, senior vice president of research for Isis, those drugs are not disease-modifying options